Sonoma Pharmaceuticals, Inc. (SNOA)
USD 3.38
(-4.52%)
USD 3.38
(-4.52%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 4.74 Million USD | 5.99% |
| 2023 | 4.47 Million USD | 12.12% |
| 2022 | 3.99 Million USD | -39.12% |
| 2021 | 6.55 Million USD | -21.29% |
| 2020 | 8.33 Million USD | -6.16% |
| 2019 | 8.88 Million USD | 21.48% |
| 2018 | 7.31 Million USD | 28.97% |
| 2017 | 5.66 Million USD | -21.39% |
| 2016 | 7.21 Million USD | -1.07% |
| 2015 | 7.28 Million USD | -13.21% |
| 2014 | 8.39 Million USD | -21.84% |
| 2013 | 10.74 Million USD | 23.28% |
| 2012 | 8.71 Million USD | 41.9% |
| 2011 | 6.14 Million USD | 58.35% |
| 2010 | 3.87 Million USD | 38.4% |
| 2009 | 2.8 Million USD | 158.49% |
| 2008 | 1.08 Million USD | -29.79% |
| 2007 | 1.54 Million USD | 166.61% |
| 2006 | -2.31 Million USD | -7.02% |
| 2005 | -2.16 Million USD | -340.13% |
| 2004 | 902 Thousand USD | 28.49% |
| 2003 | 702 Thousand USD | -40.76% |
| 2002 | 1.18 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 1.46 Million USD | 47.47% |
| 2024 Q1 | 1.2 Million USD | 39.35% |
| 2024 Q2 | 990 Thousand USD | -17.77% |
| 2024 FY | 4.74 Million USD | 5.99% |
| 2024 Q4 | 1.09 Million USD | -25.27% |
| 2023 Q2 | 1.33 Million USD | -7.61% |
| 2023 Q1 | 1.44 Million USD | 1406.25% |
| 2023 Q4 | 864 Thousand USD | 3.97% |
| 2023 FY | 4.47 Million USD | 12.12% |
| 2023 Q3 | 831 Thousand USD | -37.8% |
| 2022 Q2 | 1.24 Million USD | -14.59% |
| 2022 Q4 | 96 Thousand USD | -92.02% |
| 2022 FY | 3.99 Million USD | -39.12% |
| 2022 Q1 | 1.45 Million USD | 848.97% |
| 2022 Q3 | 1.2 Million USD | -3.06% |
| 2021 Q2 | 2.5 Million USD | -15.56% |
| 2021 FY | 6.55 Million USD | -21.29% |
| 2021 Q1 | 2.96 Million USD | 95.71% |
| 2021 Q4 | -194 Thousand USD | -109.72% |
| 2021 Q3 | 1.99 Million USD | -20.26% |
| 2020 Q2 | 2.29 Million USD | -3.08% |
| 2020 FY | 8.33 Million USD | -6.16% |
| 2020 Q3 | 2.15 Million USD | -5.93% |
| 2020 Q4 | 1.51 Million USD | -29.84% |
| 2020 Q1 | 2.36 Million USD | 26.24% |
| 2019 Q2 | 2.42 Million USD | 40.21% |
| 2019 Q3 | 2.84 Million USD | 17.31% |
| 2019 Q1 | 1.73 Million USD | 29.95% |
| 2019 Q4 | 1.87 Million USD | -34.14% |
| 2019 FY | 8.88 Million USD | 21.48% |
| 2018 Q3 | 2.36 Million USD | 28.14% |
| 2018 FY | 7.31 Million USD | 28.97% |
| 2018 Q4 | 1.33 Million USD | -43.75% |
| 2018 Q2 | 1.84 Million USD | 4.88% |
| 2018 Q1 | 1.76 Million USD | -9.5% |
| 2017 Q3 | 1.7 Million USD | -18.06% |
| 2017 Q4 | 1.94 Million USD | 14.13% |
| 2017 Q1 | 1.91 Million USD | 11.12% |
| 2017 FY | 5.66 Million USD | -21.39% |
| 2017 Q2 | 2.08 Million USD | 8.49% |
| 2016 Q3 | 1.52 Million USD | -27.27% |
| 2016 FY | 7.21 Million USD | -1.07% |
| 2016 Q2 | 2.09 Million USD | 11.59% |
| 2016 Q1 | 1.87 Million USD | -6.07% |
| 2016 Q4 | 1.72 Million USD | 13.62% |
| 2015 Q4 | 1.99 Million USD | 20.41% |
| 2015 Q3 | 1.65 Million USD | -4.39% |
| 2015 Q2 | 1.73 Million USD | -9.13% |
| 2015 Q1 | 1.9 Million USD | 37.82% |
| 2015 FY | 7.28 Million USD | -13.21% |
| 2014 Q3 | 2.1 Million USD | -22.03% |
| 2014 Q4 | 1.38 Million USD | -34.42% |
| 2014 FY | 8.39 Million USD | -21.84% |
| 2014 Q2 | 2.7 Million USD | 22.95% |
| 2014 Q1 | 2.2 Million USD | 0.55% |
| 2013 Q2 | 3.2 Million USD | 10.96% |
| 2013 FY | 10.74 Million USD | 23.28% |
| 2013 Q3 | 2.47 Million USD | -22.78% |
| 2013 Q1 | 2.88 Million USD | 35.08% |
| 2013 Q4 | 2.18 Million USD | -11.45% |
| 2012 Q1 | 1.94 Million USD | 0.98% |
| 2012 Q3 | 1.85 Million USD | -33.33% |
| 2012 FY | 8.71 Million USD | 41.9% |
| 2012 Q4 | 2.13 Million USD | 15.28% |
| 2012 Q2 | 2.77 Million USD | 42.53% |
| 2011 Q2 | 1.67 Million USD | 20.45% |
| 2011 Q3 | 1.14 Million USD | -31.32% |
| 2011 Q4 | 1.93 Million USD | 67.97% |
| 2011 FY | 6.14 Million USD | 58.35% |
| 2011 Q1 | 1.38 Million USD | 9.46% |
| 2010 Q3 | 691 Thousand USD | -15.01% |
| 2010 Q2 | 813 Thousand USD | -26.43% |
| 2010 FY | 3.87 Million USD | 38.4% |
| 2010 Q1 | 1.1 Million USD | 51.37% |
| 2010 Q4 | 1.26 Million USD | 83.65% |
| 2009 Q4 | 730 Thousand USD | 2.38% |
| 2009 Q3 | 713 Thousand USD | -9.06% |
| 2009 Q2 | 784 Thousand USD | 36.35% |
| 2009 Q1 | 575 Thousand USD | 157.85% |
| 2009 FY | 2.8 Million USD | 158.49% |
| 2008 FY | 1.08 Million USD | -29.79% |
| 2008 Q2 | 287 Thousand USD | 15.26% |
| 2008 Q1 | 249 Thousand USD | -35.82% |
| 2008 Q3 | 325 Thousand USD | 13.24% |
| 2008 Q4 | 223 Thousand USD | -31.38% |
| 2007 Q3 | 292 Thousand USD | -32.41% |
| 2007 Q1 | 1.16 Million USD | 55.13% |
| 2007 Q4 | 388 Thousand USD | 32.88% |
| 2007 FY | 1.54 Million USD | 166.61% |
| 2007 Q2 | 432 Thousand USD | -62.92% |
| 2006 Q2 | 541 Thousand USD | 0.0% |
| 2006 Q3 | 751 Thousand USD | 38.82% |
| 2006 Q4 | 751 Thousand USD | 0.0% |
| 2006 FY | -2.31 Million USD | -7.02% |
| 2006 Q1 | 541 Thousand USD | 59.59% |
| 2005 Q2 | 339 Thousand USD | 0.0% |
| 2005 Q3 | 339 Thousand USD | 0.0% |
| 2005 FY | -2.16 Million USD | -340.13% |
| 2005 Q1 | 339 Thousand USD | 0.0% |
| 2005 Q4 | 339 Thousand USD | 0.0% |
| 2004 FY | 902 Thousand USD | 28.49% |
| 2003 FY | 702 Thousand USD | -40.76% |
| 2002 FY | 1.18 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 73.06 Million USD | 93.506% |
| Theratechnologies Inc. | 62.12 Million USD | 92.363% |
| Safety Shot Inc | -74.45 Thousand USD | 6472.806% |
| Cosmos Health Inc. | 4.34 Million USD | -9.091% |
| Cronos Group Inc. | 6.99 Million USD | 32.126% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 98.924% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1666.007% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 98.468% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 52.917% |
| ProPhase Labs, Inc. | 16.23 Million USD | 70.78% |
| Dynavax Technologies Corporation | 182.11 Million USD | 97.395% |
| Radius Health, Inc. | 307.71 Million USD | 98.458% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -756.543% |
| Alvotech | -69.42 Million USD | 106.835% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 43.1% |
| Alpha Teknova, Inc. | 10.29 Million USD | 53.914% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 98.898% |
| SCYNEXIS, Inc. | 124.51 Million USD | 96.189% |
| Harrow Health, Inc. | 90.55 Million USD | 94.76% |
| Biofrontera Inc. | 16.62 Million USD | 71.462% |
| DURECT Corporation | 6.83 Million USD | 30.537% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.094% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 98.446% |
| OptiNose, Inc. | 62.35 Million USD | 92.39% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -55.361% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 84.051% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 85.83% |
| SIGA Technologies, Inc. | 122.09 Million USD | 96.114% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 88.662% |
| Shineco, Inc. | 882.16 Thousand USD | -437.879% |
| Phibro Animal Health Corporation | 312.48 Million USD | 98.482% |
| Procaps Group S.A. | 239.56 Million USD | 98.019% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -264.439% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 736.41% |
| Viatris Inc. | 6.43 Billion USD | 99.926% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 43.1% |
| Rockwell Medical, Inc. | 8.7 Million USD | 45.485% |
| Incannex Healthcare Limited | 12 Thousand USD | -39441.667% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 91.307% |
| Tilray Brands, Inc. | 223.35 Million USD | 97.876% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 98.545% |
| PetIQ, Inc. | 252.74 Million USD | 98.123% |
| Silver Spike Investment Corp. | 8.1 Million USD | 41.439% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.743% |
| Journey Medical Corporation | 52.52 Million USD | 90.966% |
| Alimera Sciences, Inc. | 61.17 Million USD | 92.243% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -13.214% |
| Assertio Holdings, Inc. | 125.04 Million USD | 96.205% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 69766.716% |
| Embecta Corp. | 749.9 Million USD | 99.367% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 296.874% |
| Procaps Group, S.A. | 239.56 Million USD | 98.019% |
| PainReform Ltd. | -15 Thousand USD | 31733.333% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 82.502% |
| Hempacco Co., Inc. | -1.21 Million USD | 490.267% |
| Talphera, Inc. | -4.89 Million USD | 196.936% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 99.032% |
| Alvotech | -69.42 Million USD | 106.835% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 99.331% |
| Kamada Ltd. | 52.59 Million USD | 90.978% |
| Indivior PLC | 907 Million USD | 99.477% |
| Currenc Group, Inc. | 17.35 Million USD | 72.661% |
| Evoke Pharma, Inc. | 4.97 Million USD | 4.695% |
| Flora Growth Corp. | 17.73 Million USD | 73.25% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 296.874% |
| Evolus, Inc. | 140.52 Million USD | 96.623% |
| HUTCHMED (China) Limited | 453.55 Million USD | 98.954% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 98.621% |
| Akanda Corp. | 111.44 Thousand USD | -4157.553% |